Method for producing ellagic acid-containing composition, and ellagic acid-containing composition
Through the heating treatment and acidic hydrolysis of plant raw materials and aqueous media of genus genus, the solubility of ellagic acid is improved, and the problem of insufficient solubility of ellagic acid in aqueous products is solved, and the efficient production of ellagic acid composition is achieved. Suitable for a variety of products.
Patent Information
- Application Number
- CN202380029534.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-28
- Filing Date
- 2023-03-24
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the existing methods for producing ellagic acid compositions, ellagic acid has low solubility, which is difficult to apply in aqueous products, and requires high-temperature heating treatment, which limits its application range.
By mixing the raw materials of the ellagic acid-containing plant with an aqueous medium, performing heat treatment, and hydrolyzing under acidic conditions, the solubility of ellagic acid is further improved, including concentration and drying after heating treatment. To obtain a high concentration of ellagic acid composition.
It significantly improves the solubility of ellagic acid, reduces the heating temperature, and achieves efficient dissolution in water. It is suitable for medicine, cosmetics and food applications.
Smart Images

Figure BDA0005054850280000111 
Figure BDA0005054850280000141 
Figure BDA0005054850280000181
Abstract
Description
Technical Field
[0001] The present disclosure relates to a method for producing a composition containing ellagic acid and the composition containing ellagic acid. Background Art
[0002] Ellagic acid is a promising natural compound for which various effects such as anticancer, anti-inflammatory, antioxidant, anti-obesity, and whitening effects have been reported.
[0003] For example, Patent Document 1 describes that ellagic acid has excellent physiological activities such as antioxidant effects on edible oils and fats, antimutagenic effects on microorganisms, and antitumor effects on small animals such as mice and rats, and is a useful compound in the food and pharmaceutical industries.
[0004] However, ellagic acid has low solubility in water and is difficult to apply to aqueous products. Therefore, studies have been conducted to improve the solubility of ellagic acid.
[0005] For example, Patent Document 2 discloses a method for producing an ellagic acid composition, which includes: a step of mixing a raw material containing a guava leaf extract and containing 1 to 5 mass % of free ellagic acid in the solid content with an aqueous medium to prepare a heat-treated raw material; and a step of heating the above-mentioned heat-treated raw material at 100 to 180°C.
[0006] Prior art literature
[0007] Patent Literature
[0008] Patent Document 1: Japanese Patent Application Laid-Open No. 05-331183
[0009] Patent Document 2: Japanese Patent Application Publication No. 2015-033375 Summary of the invention
[0010] Problems to be solved by the invention
[0011] However, the method of Patent Document 2 is limited to a raw material containing guava leaf extract and containing 1 to 5% by mass of free ellagic acid in the solid content. In addition, the method of Patent Document 2 requires heating at a high temperature of 100 to 180° C. Therefore, a new method for producing an ellagic acid-containing composition that can improve the solubility of ellagic acid is required.
[0012] Therefore, the present disclosure has been made in view of at least one of the above-mentioned problems, and an object of the present disclosure is to provide a method for producing a novel ellagic acid-containing composition capable of improving the solubility of ellagic acid.
[0013] Means for solving problems
[0014] The following are examples of the present embodiment.
[0015] (1) A method for producing a composition containing ellagic acid, comprising:
[0016] a step of preparing a solution containing at least a raw material derived from a plant of the genus Terminalia containing ellagic acid and an aqueous medium; and
[0017] A step of subjecting the above solution to a heat treatment.
[0018] (2) The production method according to (1), further comprising: performing a hydrolysis step of hydrolyzing ellagitannins contained in the raw material to produce more ellagic acid,
[0019] The solution subjected to the above-mentioned hydrolysis treatment is subjected to a heating treatment.
[0020] (3) The production method according to (2), wherein the hydrolysis treatment is hydrolysis by an acid.
[0021] (4) The production method according to any one of (1) to (3), wherein the solution further contains ellagic acid added separately from ellagic acid contained in the raw material derived from the plant of the genus Terminalia.
[0022] (5) The production method according to any one of (1) to (4), wherein the plant of the genus Terminalia is Terminalia catappa.
[0023] (6) A production method according to any one of (1) to (5), wherein the raw material from the Terminalia genus plant is at least one material selected from the leaves, fruits, trunks and branches of the Terminalia genus plant, or an extract extracted from at least one material selected from the leaves, fruits, trunks and branches of the Terminalia genus plant using an extraction medium.
[0024] (7) The production method according to any one of (1) to (6), wherein the raw material derived from the Terminalia genus plant is an extract extracted from at least one material selected from the group consisting of leaves, fruits, trunks, and branches of the Terminalia genus plant using an extraction medium.
[0025] (8) The production method according to (6) or (7), wherein the extraction medium is water, an aqueous medium, or a mixed solvent thereof.
[0026] (9) The production method according to any one of (6) to (8), wherein the extraction medium is water, alcohol, or a mixed solvent of water and alcohol.
[0027] (10) The production method according to any one of (1) to (9), wherein the temperature of the heat treatment is 60° C. or higher.
[0028] (11) The production method according to any one of (1) to (10), wherein the temperature of the heat treatment is lower than 100°C.
[0029] (12) The production method according to any one of (1) to (11), wherein the aqueous medium in the solution is water, alcohol, or a mixed solvent of water and alcohol.
[0030] (13) The production method according to any one of (1) to (12), further comprising the step of concentrating the solution after the step of performing the heat treatment.
[0031] (14) The production method according to any one of (1) to (13), wherein the concentration of ellagic acid dissolved in the solution obtained by the step of performing a heating treatment or the step of performing a concentration treatment is 50 μg / mL or more.
[0032] (15) The production method according to any one of (1) to (14), further comprising a step of drying the solution to obtain a solid containing ellagic acid after the step of performing a heating treatment or after the step of performing a concentration treatment in the case of performing a concentration treatment.
[0033] (16) An ellagic acid-containing composition obtained by the production method according to any one of (1) to (15).
[0034] (17) A medicine, cosmetic, quasi-drug, or food or beverage comprising the ellagic acid-containing composition according to (16).
[0035] (18) A use of a raw material derived from a plant of the genus Terminalia for solubilizing ellagic acid, wherein a solution containing the raw material derived from a plant of the genus Terminalia and an aqueous medium is subjected to a heat treatment in the presence of ellagic acid.
[0036] Effects of the Invention
[0037] The present disclosure can provide a novel method for producing an ellagic acid-containing composition capable of improving the solubility of ellagic acid. DETAILED DESCRIPTION
[0038] The present embodiment provides a method for producing an ellagic acid-containing composition, comprising: preparing a solution containing at least a raw material derived from a plant of the genus Terminalia containing ellagic acid and an aqueous medium; and heating the solution.
[0039] By using this embodiment, a method for manufacturing a new ellagic acid-containing composition that can improve the solubility of ellagic acid can be provided. The inventors and others found that by heating a solution containing a raw material from a plant of the genus Terminalia and an aqueous medium in the presence of ellagic acid, the effect of solubilizing ellagic acid can be obtained, thereby completing this embodiment. As a reason why the solubilizing effect of ellagic acid can be obtained by heating a solution containing a raw material from a plant of the genus Terminalia and ellagic acid, it is speculated that the ingredients contained in the raw material act on ellagic acid due to the heating treatment, so that ellagic acid is solubilized. It is speculated that the ingredients contained in the raw material act on ellagic acid by the formation of inclusion complexes, the formation of salts, or the formation of associations. It should be noted that this embodiment is not limited by this speculation.
[0040] Hereinafter, the production method of this embodiment will be described in detail.
[0041] This embodiment has a step of preparing a solution containing a raw material derived from a plant of the genus Terminalia containing at least ellagic acid and an aqueous medium.
[0042] The method for preparing the solution is not particularly limited, and examples thereof include a method of preparing the solution by mixing at least a raw material derived from a plant of the genus Terminalia and an aqueous medium, a method of preparing the solution by purchasing the solution, and the like.
[0043] The plant of the genus Terminalia is a tree containing a high content of ellagic acid. In the present embodiment, the plant of the genus Terminalia is preferably Terminalia catappa from the viewpoint of containing a high content of ellagic acid.
[0044] In this specification, ellagic acid is used to include free ellagic acid, its salts and solvates (including hydrates). It should be noted that in the Terminalia genus, there are a large number of ellagic tannins having a structure in which ellagic acid and sugar are bonded. In this specification, ellagic acid and ellagic tannins are used separately.
[0045] The raw material from the Terminalia genus plant is not particularly limited, and examples thereof include at least one material selected from the leaves, fruits, trunks and branches of the Terminalia genus plant, and extracts extracted from at least one material selected from the leaves, fruits, trunks and branches of the Terminalia genus plant using an extraction medium. As the at least one material selected from the leaves, fruits, trunks and branches, for example, cut products, crushed products, ground products, pulverized products, etc. can be used. One material can be used alone, or two or more materials can be used in combination.
[0046] The extract from the Terminalia genus can be prepared by extracting the components from at least one material selected from the group consisting of leaves, fruits, trunks and branches using an extraction medium (e.g., an aqueous medium such as water or ethanol). As the raw material from the Terminalia genus, an extract is preferably used, and an extract extracted using water, an aqueous medium or a mixed solvent thereof as an extraction medium is particularly preferred. The extract from the Terminalia genus contains a high content of ellagic acid from the Terminalia genus.
[0047] The extract from the plant of the genus Terminalia is preferably a Terminalia leaf extract. Terminalia leaf is a material containing a high content of ellagic acid from Terminalia. The Terminalia leaf extract is preferably an extract extracted using water, an aqueous medium or a mixed solvent thereof as an extraction medium.
[0048] There are no particular restrictions on the extraction method, and examples thereof include ultrasonic extraction, microwave extraction, solid-liquid extraction, liquid-liquid extraction, immersion extraction, boiling extraction, leaching extraction, steam distillation extraction, reflux extraction, stirring extraction, etc. In addition, the extraction method may be heating extraction, room temperature extraction, or low temperature extraction. The extraction temperature is not particularly limited, but is preferably above 0°C, preferably above 20°C, from the perspective of improving the extraction efficiency. In addition, the extraction temperature is, for example, below 100°C.
[0049] There are no particular restrictions on the extraction medium, and examples thereof include aqueous media such as water (including water vapor) or alcohol, subcritical or supercritical carbon dioxide, edible oils such as soybean oil, rapeseed oil, sunflower oil, palm oil or lard. Among them, water, an aqueous medium or a mixed solvent thereof is preferably used as the extraction medium. As alcohol belonging to the aqueous medium, for example, ethanol or propanol can be mentioned. For example, a 30-70 v / v% ethanol aqueous solution can also be used as the extraction medium. In addition, a solvent in which an acid or a base is added to the above-mentioned extraction solvent to adjust the pH can also be used. One type of extraction medium can be used alone, or two or more types can be used in combination.
[0050] The extract may be used directly as the extracted solution, or may be purified, concentrated (decompressed concentration, membrane concentration, etc.), diluted, filtered, etc. as needed. In addition, the extracted solution may be spray dried, freeze dried, concentrated and dried to solidify, and used as a dry product. For example, the extract may be prepared in the form of an extract containing an extraction medium or in the form of a solid product (e.g., a freeze dried product, a spray dried product) from which the extraction medium has been removed.
[0051] The content of ellagic acid in the extract is preferably 2% or more, preferably 5% or more, and preferably 10% or more, based on dry weight. In addition, the content of ellagic acid in the extract is preferably 25% or less, preferably 20% or less, and preferably 15% or less, based on dry weight.
[0052] The aqueous medium is water, an organic solvent that is uniformly mixed with water, or a mixed solvent thereof. Examples of water include tap water, distilled water, ion exchange water, and purified water. Water may also contain solutes such as salts, sugars, and pH adjusters. There are no particular restrictions on the organic solvent as long as it is a solvent that is uniformly mixed with water, and examples thereof include alcohols. Examples of alcohols include monohydric alcohols such as ethanol or propanol, dihydric alcohols such as propylene glycol or butanediol, and trihydric alcohols such as glycerol. For example, a 30 to 70 v / v% ethanol aqueous solution may be used as the aqueous medium. One aqueous medium may be used alone, or two or more may be used in combination.
[0053] One mode of this embodiment may further include a step of performing a hydrolysis treatment to hydrolyze the ellagitannins contained in the raw material to produce more ellagic acid. In this case, the solution subjected to the hydrolysis treatment is subjected to a heating treatment described later. By hydrolyzing the ellagitannins contained in the raw material, the concentration of ellagic acid in the solution can be further increased.
[0054] The hydrolysis treatment is not particularly limited as long as it can hydrolyze the ellagitannins contained in the raw material to produce more ellagic acid, and examples thereof include hydrolysis by acid, hydrolysis by enzyme, etc. The hydrolysis can be further accelerated by the heat treatment described below.
[0055] Regarding the hydrolysis by acid, the acid is added to hydrolyze the ellagitannins contained in the raw material to generate ellagic acid. In addition, the hydrolysis by acid can be further accelerated by the heat treatment described below.
[0056] The acid is not particularly limited, and examples thereof include hydrochloric acid and sulfuric acid. The acid may be used alone or in combination of two or more.
[0057] In the case of acid hydrolysis, the pH (20°C) of the solution is not particularly limited as long as the hydrolysis reaction occurs, and is, for example, 5 or less. The pH (20°C) of the solution is preferably 4 or less, preferably 3 or less, preferably 2 or less, and preferably 1 or less from the viewpoint of efficiently causing the hydrolysis reaction of ellagitannins.
[0058] Regarding the hydrolysis based on enzymes, as the enzyme used in the hydrolysis, there is no particular limitation as long as it can hydrolyze ellagitannins to generate ellagic acid, and for example, tannase can be cited. Tannase can be separated or prepared from fungi or bacterial sources, for example. As tannase, for example, tannase obtained by culturing tannase-producing bacteria of the genus Aspergillus, the genus Penicillium, and the genus Rhizopus can be exemplified. Among them, tannase from Aspergillus oryzae is preferred. The concentration of tannase in the solution is not particularly limited, for example, 10 Unit / L to 500 Unit / L, preferably 20 Unit / L to 150 Unit / L.
[0059] In one embodiment of the present invention, the solution may further contain ellagic acid added in addition to the ellagic acid contained in the raw material from the genus Terminalia. One embodiment of the present invention may include a step of further adding ellagic acid to the solution in addition to the ellagic acid contained in the raw material, thereby obtaining an ellagic acid-containing composition having a higher ellagic acid concentration.
[0060] Regarding the amount of ellagic acid added to the solution, from the viewpoint of increasing the ellagic acid concentration in the obtained ellagic acid-containing composition, it is preferred to add ellagic acid so that the content of ellagic acid in the solution after addition is preferably 5% by mass or more, preferably 6% by mass or more, preferably 7% by mass or more, preferably 8% by mass or more, preferably 9% by mass or more, preferably 10% by mass or more, based on the solid content. In addition, regarding the amount of ellagic acid added to the solution, it is preferred to add ellagic acid so that the content of ellagic acid in the solution after addition is preferably 20% by mass or less, preferably 19% by mass or less, preferably 18% by mass or less, preferably 17% by mass or less, preferably 16% by mass or less, preferably 15% by mass or less, based on the solid content.
[0061] The addition of ellagic acid can be carried out by adding a compound composed of ellagic acid (including free ellagic acid, its salt and solvate) itself, or by adding a material containing ellagic acid (e.g., an extract from a certain plant). For example, ellagic acid is sold by Fujifilm and Wako Pure Chemical Industries, Ltd., and ellagic acid dihydrate is sold by Tokyo Chemical Industry Co., Ltd. In addition, as a material containing ellagic acid, for example, pomegranate ellagic acid is sold by Sabinsa Japan Corporation.
[0062] The method of performing the hydrolysis treatment and the method of further adding ellagic acid can be appropriately combined. Thus, the obtained ellagic acid-containing composition can contain ellagic acid from ellagic acid contained in the raw material, ellagic acid produced by the hydrolysis reaction of ellagic tannins, and ellagic acid added separately from ellagic acid contained in the raw material from the Terminalia plant, and can have a higher ellagic acid concentration.
[0063] Regarding the content of the raw material (especially the extract) from the genus Terminalia in the solution, from the aspect of improving the solubility of ellagic acid, it is preferably 60% by mass or more, preferably 70% by mass or more, and preferably 80% by mass or more, based on the solid content. In addition, the content of the raw material (especially the extract) from the genus Terminalia in the solution is preferably 100% by mass or less, preferably less than 100% by mass, and preferably 99% by mass or less. It should be noted that, regarding the solid content of the raw material from the genus Terminalia in this specification, when the raw material from the genus Terminalia is in the form of a solid, it is set to its dry mass, and in the case of other than the form of a solid (for example, a liquid or paste), it is set to the mass after the raw material from the genus Terminalia is dried in an electric constant temperature dryer at 105°C for 3 hours to remove the volatile components.
[0064] The total content of the solid components in the solution is not particularly limited, but is, for example, 0.5 g / L or more and 50 g / L or less.
[0065] In the solution, other components may also be included in addition to the above components. Other components may be added to a degree that does not hinder the effect of the present embodiment, and the content of other components in the solution is, for example, 20% by mass or less, preferably 15% by mass or less, preferably 10% by mass or less, preferably 5% by mass or less, preferably 1% by mass or less. As other components, for example, an organic solvent in a solution containing ellagic acid used to make the solution contain a predetermined amount of ellagic acid can be cited.
[0066] This embodiment includes a step of subjecting the solution to a heating treatment.
[0067] As described above, the solubilization effect of ellagic acid can be obtained by the heat treatment. As the reason, it is speculated that the components contained in the raw material act on ellagic acid through the formation of inclusion complexes, the formation of salts, or the formation of associations due to the heat treatment, so that ellagic acid is solubilized. It should be noted that the present embodiment is not limited by this speculation.
[0068] Regarding the temperature of the heat treatment, from the aspect of improving the solubility of ellagic acid, it is preferably 60 °C or higher, preferably 65 °C or higher, preferably 70 °C or higher, preferably 75 °C or higher, preferably 80 °C or higher. In addition, regarding the temperature of the heat treatment, from the viewpoint of the thermal stability of the components, it is preferably 180 °C or lower, preferably 170 °C or lower, preferably 160 °C or lower. Furthermore, regarding the temperature of the heat treatment, mainly from the viewpoint of energy consumption, it is preferably below 100 °C, preferably 99 °C or lower, preferably 98 °C or lower. In this embodiment, even when the temperature of the heat treatment is below 100 °C, an excellent ellagic acid solubilization effect can be obtained, which is particularly excellent in this regard. The time of the heat treatment can also vary depending on the treatment method and temperature, for example, it is 10 minutes to 10 hours. These conditions of temperature and time are merely illustrative, and can be appropriately set considering the mutual relationship between temperature and time, other factors, etc. It should be noted that the enzyme used in the hydrolysis treatment can also be inactivated during this heat treatment.
[0069] The heat treatment method is not particularly limited, and known methods can be applied. In addition, heating can be carried out under normal pressure and under pressure. In addition, the heat treatment can also be carried out by steam heating treatment, and a continuous or batch steam generator (Japanese original text: スチ一マ一), autoclave, etc. can also be used.
[0070] The solution subjected to the heat treatment can be appropriately cooled. The temperature of the cooled solution is preferably 50 °C or lower, preferably 30 °C or lower. The cooling method is not particularly limited, for example, it can be cooling using a cooler, cooling by placing at room temperature.
[0071] The concentration of ellagic acid in the solution obtained after the heat treatment is preferably 50 μg / mL or higher, preferably 60 μg / mL or higher, preferably 70 μg / mL or higher, preferably 80 μg / mL or higher, preferably 90 μg / mL or higher, preferably 100 μg / mL or higher.
[0072] In the above description, as the processes of the present embodiment, at least the process of preparing a solution, the process of implementing a hydrolysis treatment, and the process of implementing a heating treatment are shown. There is no particular limitation on their order as long as the effect of the present embodiment is not hindered. For example, the present embodiment basically assumes that the process of preparing a solution, the process of implementing a hydrolysis treatment, and the process of implementing a heating treatment are performed separately, and they do not necessarily have to be performed separately in this order. For example, the present embodiment may also include a case where the process of preparing a solution and the process of implementing a heating treatment are performed simultaneously. As a specific example, a raw material from a plant of the genus Terminalia can be added while heating an aqueous medium. In addition, for example, the present embodiment may also include a case where the process of preparing a solution and the process of implementing a hydrolysis treatment are performed simultaneously. As a specific example, a raw material from a plant of the genus Terminalia can be added to a liquid containing an aqueous medium and an acid or an enzyme. In addition, for example, the present embodiment may also include a case where the process of implementing a hydrolysis treatment and the process of implementing a heating treatment are performed simultaneously. As a specific example, an acid or an enzyme can be added while heating the solution. In addition, for example, the present embodiment may also include a case where the process of preparing a solution, the process of implementing a hydrolysis treatment, and the process of implementing a heating treatment are performed simultaneously. As a specific example, the raw material from the Terminalia genus plant can be added while heating the liquid containing the aqueous medium, acid or enzyme. In addition, in the above description, it is shown that the above solution can further contain ellagic acid added separately from the ellagic acid contained in the raw material from the Terminalia genus plant. The ellagic acid added separately can be contained in the solution of the process of preparing the solution, can also be contained in the solution of the process of implementing the hydrolysis treatment, and can also be contained in the solution of the process of implementing the heating treatment. As long as the ellagic acid added separately is present in the solution during the heating treatment, there is no particular limitation.
[0073] The obtained solution may be subjected to purification treatment, concentration treatment, drying treatment, etc. as necessary to obtain an ellagic acid-containing composition.
[0074] This embodiment may include, as a purification treatment, a step of removing the solid portion remaining without dissolving from the solution subjected to the above-mentioned heat treatment. The removal method is not particularly limited, and examples thereof include centrifugal separation, decantation, or filtration.
[0075] This embodiment may include a step of concentrating the solution subjected to the above-mentioned heat treatment as a concentration treatment. The ellagic acid-containing composition may be in the form of a solution or a paste. As a method for concentrating the solution, general methods such as reduced pressure concentration (e.g., reduced pressure centrifugation) or membrane concentration may be cited.
[0076] The ellagic acid concentration of the ellagic acid-containing composition after the concentration treatment can be, for example, 500 μg / mL or more. The ellagic acid concentration of the ellagic acid-containing composition after the concentration treatment is preferably 750 μg / mL or more, preferably 800 μg / mL or more, preferably 850 μg / mL or more, preferably 900 μg / mL or more, preferably 950 μg / mL or more. The ellagic acid-containing composition obtained in this embodiment has no precipitation of ellagic acid even after concentration due to the solubilizing effect of ellagic acid, and can exist in a state where ellagic acid is dissolved.
[0077] This embodiment can be a step of drying the solution to obtain a solid containing ellagic acid as a drying treatment. The ellagic acid-containing composition can be in the form of a solid such as a powder or granules. As a method for removing the medium, for example, freeze drying, evaporative drying solidification or spray drying can be cited. The drying process can also be carried out after the concentration process. The obtained solid can be classified, granulated, crushed, etc. as needed.
[0078] The ellagic acid-containing composition of the present embodiment obtained in the form of a solid has excellent solubility of ellagic acid in water even when it is added to water again. This result shows that even when the ellagic acid-containing composition of the present embodiment is made into a solid, ellagic acid is present in the solid in a form that is easily solubilized.
[0079] One embodiment of the present invention may be a composition containing ellagic acid obtained by the manufacturing method of the present invention. In addition, one embodiment of the present invention may be a pharmaceutical, cosmetic, quasi-drug or food containing the ellagic acid composition. In the present embodiment, the so-called food and drink, in addition to general food and drink, is also used in the sense of food (such as health food, functional food, health functional food or special purpose food) that can be taken for the purpose of maintaining and promoting health other than pharmaceuticals and quasi-drugs. Among health foods, foods provided under the names of nutritional supplements, health supplements, nutritional supplements, etc. are included. Health functional foods include specific health foods and nutritional functional foods defined by the Japanese Food Sanitation Law or the Japanese Food Promotion Law that can show specific health effects, functions of nutrients, reduction of disease risks, etc. The form of the food and drink can be suitable for consumption, such as any one of solid, liquid, granular, granular, powdery, capsule, paste, and paste.
[0080] Example
[0081] Hereinafter, the present embodiment will be described using examples. It should be noted that the specific aspects of the present embodiment are not limited to those of the examples, and the configuration may be appropriately changed within a range that does not impair the gist of the present disclosure.
[0082] [Measurement method]
[0083] (Ellagic acid concentration)
[0084] For the quantification of free ellagic acid, a liquid chromatograph manufactured by Thermo SCIENTIFIC was used, equipped with an ACQUITY column manufactured by Waters. TM PREMIER HSS T3 (2.1×100 mm) was used for the gradient method at a column temperature of 40° C. The mobile phase A was 0.05% acetic acid aqueous solution, and the mobile phase B was acetonitrile containing 0.05% acetic acid, and the flow rate was 250 μL / min. The gradient conditions are as follows.
[0085] [Table 1]
[0086]
[0087] The sample injection volume was set to 2 μL, and quantification was performed using absorbance at a wavelength of 252 nm.
[0088] (pH)
[0089] After the sample temperature was adjusted to 20° C., the pH was measured using a pH meter (SPH70, ASONE).
[0090] (Preparation Example 1: 50% ethanol extract)
[0091] As a plant of the genus Terminalia, a crushed material of Terminalia leaf (collection site: Heianza Island (Yonajo Heianza, Uruma City, Okinawa Prefecture)) was used. A dispersion was prepared by adding 5 mL of a 50% ethanol aqueous solution to 100 mg of the crushed material of the Terminalia leaf. Then, the dispersion was subjected to an ultrasonic treatment for 1 hour. Then, the dispersion after the ultrasonic treatment was filtered to obtain an extract. Thereafter, the extract was concentrated using a reduced pressure centrifuge, and then freeze-dried to obtain a freeze-dried product. The freeze-dried product was used as an extract from a plant of the genus Terminalia. When used in the following experiment, a solution containing the extract (10 mg / mL) prepared as follows was used, that is, the freeze-dried product was dissolved and dispersed in a 50% ethanol aqueous solution to a concentration of 10 mg / mL.
[0092] (Preparation Example 2: Water Extract)
[0093] As a plant of the genus Terminalia, a crushed material of Terminalia leaf (collection site: Heianza Island (Yonajo Heianza, Uruma City, Okinawa Prefecture)) was used. 5 mL of pure water was added to 100 mg of the crushed material of Terminalia leaf to prepare a dispersion. Then, the dispersion was subjected to an ultrasonic treatment for 1 hour. Then, the dispersion after the ultrasonic treatment was filtered to obtain an extract. Thereafter, the extract was concentrated using a reduced pressure centrifuge, and then freeze-dried to obtain a freeze-dried product. The freeze-dried product was used as an extract from a plant of the genus Terminalia. When used in the following experiment, a solution containing the extract (10 mg / mL) prepared as follows was used, that is, the freeze-dried product was dissolved and dispersed in pure water to a concentration of 10 mg / mL.
[0094] (Preparation Example 3: 100% ethanol extract)
[0095] As a plant of the genus Terminalia, a crushed material of Terminalia leaf (collection site: Heianza Island (Yonajo Heianza, Uruma City, Okinawa Prefecture)) was used. 5 mL of 100% ethanol was added to 100 mg of the crushed material of Terminalia leaf to prepare a dispersion. Then, the dispersion was subjected to an ultrasonic treatment for 1 hour. Then, the dispersion after the ultrasonic treatment was filtered to obtain an extract. Thereafter, the extract was concentrated using a reduced pressure centrifuge, and then freeze-dried to obtain a freeze-dried product. The freeze-dried product was used as an extract from a plant of the genus Terminalia. When used in the following experiment, a solution containing the extract (10 mg / mL) prepared as follows was used, that is, the freeze-dried product was dissolved and dispersed in a 100% ethanol aqueous solution to a concentration of 10 mg / mL.
[0096] (Preparation Example 4: Solution containing ellagic acid)
[0097] Ellagic acid produced by Fujifilm Wako Pure Chemical Industries, Ltd. (Cat. No. 057-08751) was used. When used in the experiment, an ellagic acid-containing solution (1 mg / mL) prepared by dissolving ellagic acid in pyridine to a concentration of 1 mg / mL was used.
[0098] [Study on the increase of ellagic acid concentration based on hydrolysis]
[0099] (Example 1)
[0100] In a 1.5 mL tube, a solution was prepared by mixing 50 μL of the extract-containing solution (10 mg / mL, containing 50% ethanol extract) prepared in Preparation Example 1 above (equivalent to 500 μg of the extract) with 50 μL of pyridine. The solvent was removed from the solution in the tube by performing a reduced-pressure centrifugation treatment to prepare an extract-containing powder. Then, 500 μL of hydrochloric acid (2N) was added to the tube and mixed with the extract-containing powder to prepare a mixed solution. Then, the tube containing the mixed solution was placed in a dry bath incubator and incubated at 95 °C for 4 hours to perform a hydrolysis treatment. Then, the incubated mixed solution was left in the surrounding environment to return to room temperature (23 °C). Thereafter, the mixed solution was filtered through a 0.45 μm filter to remove solids, obtaining a liquid composition E1.
[0101] (Comparative Example 1)
[0102] In a 1.5 mL tube, a solution was prepared by mixing 50 μL of the extract-containing solution (10 mg / mL, containing 50% ethanol extract) prepared in Preparation Example 1 above (equivalent to 500 μg of the extract) with 50 μL of pure water. The solvent was removed from the solution in the tube by performing a reduced-pressure centrifugation treatment to prepare an extract-containing powder. Then, 500 μL of pure water was added to the tube and mixed to prepare a mixed solution. The mixed solution was filtered through a 0.45 μm filter to remove solids, obtaining a liquid composition C1.
[0103] (Comparative Example 2)
[0104] The same operation as in Comparative Example 1 was performed except that DMSO was added instead of pure water, obtaining a liquid composition C2.
[0105] (Comparative Example 3)
[0106] In a 1.5 mL tube, a solution was prepared by mixing 50 μL of the ellagic acid-containing solution (1 mg / mL) prepared in Preparation Example 4 above (equivalent to 50 μg of ellagic acid) with 50 μL of a 50% ethanol aqueous solution. The solvent was removed from the solution in the tube by performing a reduced-pressure centrifugation treatment to prepare an ellagic acid-containing powder. Then, 500 μL of hydrochloric acid (2N) was added to the tube and mixed with the ellagic acid-containing powder to prepare a mixed solution. Then, the tube containing the mixed solution was placed in a dry bath incubator and incubated at 95 °C for 4 hours. Then, the incubated mixed solution was left in the surrounding environment to return to room temperature (23 °C). Thereafter, the mixed solution was filtered through a 0.45 μm filter to remove solids, obtaining a liquid composition C3.
[0107] (Comparative Example 4)
[0108] In a 1.5 mL tube, a solution was prepared by mixing 50 μL of the ellagic acid-containing solution (1 mg / mL) prepared in the above-mentioned Preparation Example 4 (equivalent to 50 μg of ellagic acid) with 50 μL of a 50% ethanol aqueous solution. The solution in the tube was subjected to reduced pressure centrifugation to remove the solvent, and a powder containing ellagic acid was prepared. Then, 500 μL of pure water was added to the above-mentioned tube and mixed with the ellagic acid-containing powder to prepare a mixed solution. The mixed solution was filtered with a 0.45 μm filter to remove solids, and a liquid composition C4 was obtained.
[0109] (Comparative Example 5)
[0110] A liquid composition C5 was obtained in the same manner as in Comparative Example 4 except that DMSO was added instead of pure water.
[0111] (evaluate)
[0112] The ellagic acid concentration of the obtained liquid composition was measured according to the above-mentioned measurement method.
[0113] [Table 2]
[0114]
[0115] (Inspection)
[0116] The liquid composition E1 obtained in Example 1 is a composition obtained by subjecting a mixed solution prepared by adding hydrochloric acid to an extract from a plant of the genus Terminalia to a hydrolysis treatment based on heating. The concentration of ellagic acid in the solution obtained after the hydrolysis treatment is 114.5 μg / mL, and it is dissolved in the solution at a high concentration. Since the solubility of ellagic acid in water is about 20 μg / mL, it can be seen that ellagic acid is solubilized far exceeding the solubility in Example 1. It should be noted that in Example 1, after the solution containing the extract (10 mg / mL) is mixed with pyridine, the solvent is removed by reduced pressure centrifugation, but the mixing operation with pyridine is an operation performed in association with the experimental examples described later from the viewpoint of conditions, etc., and is an operation that can be omitted in the present embodiment.
[0117] As an examination of Comparative Example 1, the ellagic acid concentration of the liquid composition E1 of Example 1 was 114.5 μg / mL, whereas the ellagic acid concentration of the liquid composition C1 of Comparative Example 1 was 27.6 μg / mL. This is considered to be because, in Example 1, the extract from the genus Terminalia was subjected to a hydrolysis treatment by heating in the presence of hydrochloric acid, so that the ellagic tannin contained in the extract was hydrolyzed to generate ellagic acid, and the generated ellagic acid was solubilized by the action of the components contained in the extract from the genus Terminalia, and exceeded the saturation concentration in water.
[0118] As an examination of Comparative Example 2, since DMSO, which has excellent solubility of ellagic acid, was used as a solvent in Comparative Example 2, it can be considered that the ellagic acid concentration of the liquid composition C2 of Comparative Example 2 shows the content of ellagic acid originally contained in the extract. The ellagic acid concentration of the liquid composition E1 of Example 1 was 114.5 μg / mL, and the ellagic acid concentration of the liquid composition C2 of Comparative Example 2, which shows the content of ellagic acid originally contained in the extract, was 27.7 μg / mL. This can be considered to be because, in Example 1, the ellagic tannin contained in the extract was hydrolyzed to generate ellagic acid.
[0119] The liquid composition C3 of Comparative Example 3 is a composition obtained by adding hydrochloric acid to a solution containing ellagic acid (without an extract from a plant of the genus Terminalia) and heating it, indicating that a composition containing high concentrations of ellagic acid cannot be obtained by simply heating in hydrochloric acid without an extract from a plant of the genus Terminalia. Comparative Examples 4 and 5 are given as controls for the case of using pure water or DMSO, and in Example 1, a high concentration of ellagic acid was achieved to the same degree as that of the liquid composition C5 of Comparative Example 5 using DMSO.
[0120] [Study on improving the solubility of ellagic acid 1]
[0121] (Example A1)
[0122] In a 1.5 mL tube, a solution was prepared by mixing 50 μL of the solution containing ellagic acid (1 mg / mL) prepared in the above-mentioned Preparation Example 4 (equivalent to 50 μg of ellagic acid) with 50 μL of the solution containing the extract (10 mg / mL, containing 50% ethanol extract) prepared in the above-mentioned Preparation Example 1 (equivalent to 500 μg of extract). The solution in the tube was subjected to reduced pressure centrifugation to remove the solvent, and a powder containing ellagic acid + extract was prepared. Then, 500 μL of pure water was added to the tube and mixed with the powder containing ellagic acid + extract to prepare a mixed solution. Then, the tube containing the mixed solution was placed in a dry bath and incubated at 95°C for 20 minutes. Then, the incubated mixed solution was placed in the surrounding environment and returned to room temperature (23°C). Thereafter, the mixed solution was filtered with a 0.45 μm filter to remove solids to obtain a liquid composition E-A1.
[0123] (Example A2)
[0124] A liquid composition E-A2 was obtained in the same manner as in Example A1 except that the heating temperature in the dry bath was changed to 75°C.
[0125] (Example A3)
[0126] Liquid composition E-A3 was obtained in the same manner as in Example A1, except that heating at 121° C. was performed using an autoclave instead of heating with a dry bath.
[0127] (Example A4)
[0128] A liquid composition E-A4 was obtained in the same manner as in Example A1 except that the heating temperature in the dry bath was changed to 55°C.
[0129] (Comparative Example A1)
[0130] A liquid composition C-A1 was obtained in the same manner as in Example A1, except that the mixture was left at room temperature (23° C.) for 20 minutes without heating with a dry bath.
[0131] (Example B1)
[0132] In a 1.5 mL tube, a solution was prepared by mixing 50 μL of pyridine (without ellagic acid added) and 50 μL of the extract-containing solution (10 mg / mL, containing 50% ethanol extract) prepared in the above-mentioned Preparation Example 1 (equivalent to 500 μg of extract). The solution in the tube was subjected to reduced pressure centrifugation to remove the solvent, and a powder containing the extract was prepared. Then, 500 μL of pure water was added to the tube and mixed with the extract-containing powder to prepare a mixed solution. Then, the tube containing the mixed solution was placed in a dry bath and incubated at 95°C for 20 minutes. Then, the incubated mixed solution was placed in the surrounding environment and returned to room temperature (23°C). Thereafter, the mixed solution was filtered with a 0.45 μm filter to remove solids to obtain a liquid composition E-B1.
[0133] (Example B2)
[0134] A liquid composition E-B2 was obtained in the same manner as in Example B1 except that the heating temperature in the dry bath was changed to 75°C.
[0135] (Example B3)
[0136] Liquid composition E-B3 was obtained in the same manner as in Example B1, except that heating at 121° C. was performed using an autoclave instead of heating in a dry bath.
[0137] (Example B4)
[0138] A liquid composition E-B4 was obtained in the same manner as in Example B1 except that the heating temperature in the dry bath was changed to 55°C.
[0139] (Comparative Example B1)
[0140] A liquid composition C-B1 was obtained in the same manner as in Example B1, except that the mixture was left at room temperature (23°C) for 20 minutes without heating with a dry bath.
[0141] (Comparative Example B2)
[0142] In a 1.5 mL tube, a solution was prepared by mixing 50 μL of pyridine (without ellagic acid addition) and 50 μL of the extract-containing solution (10 mg / mL, containing 50% ethanol extract) prepared in the above-mentioned Preparation Example 1 (equivalent to 500 μg of extract). The solution in the tube was subjected to reduced pressure centrifugation to remove the solvent, and a powder containing the extract was prepared. Then, 500 μL of DMSO was added to the tube and mixed with the extract-containing powder to prepare a mixed solution. Thereafter, the mixed solution was filtered with a 0.45 μm filter to remove solids, and a liquid composition C-B2 was obtained.
[0143] (Comparative Example C1)
[0144] In a 1.5 mL tube, a solution was prepared by mixing 50 μL of the ellagic acid-containing solution (1 mg / mL) prepared in the above-mentioned Preparation Example 4 (equivalent to 50 μg of ellagic acid) with 50 μL of a 50% ethanol aqueous solution (without extract added). The solution in the tube was subjected to reduced pressure centrifugation to remove the solvent, and a powder containing ellagic acid was prepared. Then, 500 μL of pure water was added to the tube and mixed with the ellagic acid-containing powder to prepare a mixed solution. Then, the tube containing the mixed solution was placed in a dry bath and incubated at 95° C. for 20 minutes. Then, the incubated mixed solution was placed in the surrounding environment and returned to room temperature (23° C.). Thereafter, the mixed solution was filtered with a 0.45 μm filter to remove solids to obtain a liquid composition C-C1.
[0145] (Comparative Example C2)
[0146] A liquid composition C-C2 was obtained in the same manner as in Comparative Example C1 except that the heating temperature in the dry bath was changed to 75°C.
[0147] (Comparative Example C3)
[0148] A liquid composition C-C3 was obtained in the same manner as in Comparative Example C1, except that heating at 121° C. was performed using an autoclave instead of heating with a dry bath.
[0149] (Comparative Example C4)
[0150] A liquid composition C-C4 was obtained in the same manner as in Comparative Example C1 except that the heating temperature in the dry bath was changed to 55°C.
[0151] (Comparative Example C5)
[0152] Liquid composition C-C5 was obtained in the same manner as in Comparative Example C1, except that the mixture was left at room temperature (23° C.) for 20 minutes without heating with a dry bath.
[0153] (Comparative Example C6)
[0154] In a 1.5 mL tube, a solution was prepared by mixing 50 μL of the ellagic acid-containing solution (1 mg / mL) prepared in the above-mentioned Preparation Example 4 (equivalent to 50 μg of ellagic acid) with 50 μL of a 50% ethanol aqueous solution (without the addition of an extract). The solution in the tube was subjected to reduced pressure centrifugation to remove the solvent, and a powder containing ellagic acid was prepared. Then, 500 μL of DMSO was added to the tube and mixed with the ellagic acid-containing powder to prepare a mixed solution. Thereafter, the mixed solution was filtered with a 0.45 μm filter to remove solids, and a liquid composition C-C6 was obtained.
[0155] (Comparative Example D1)
[0156] In a 1.5 mL tube, a solution was prepared by mixing 50 μL of the solution containing ellagic acid (1 mg / mL) prepared in the above Preparation Example 4 (equivalent to 50 μg of ellagic acid) and 50 μL of the solution containing the extract (10 mg / mL, containing 50% ethanol extract) prepared in the above Preparation Example 1 (equivalent to 500 μg of extract). The solution in the tube was subjected to reduced pressure centrifugation to remove the solvent, and a powder containing ellagic acid + extract was prepared. Then, 500 μL of DMSO was added to the tube and mixed with the powder containing ellagic acid + extract to prepare a mixed solution. Thereafter, the mixed solution was filtered with a 0.45 μm filter to remove solids to obtain a liquid composition C-D1.
[0157] (evaluate)
[0158] <Determination of ellagic acid concentration>
[0159] The ellagic acid concentration of the obtained liquid composition was measured according to the above-mentioned measurement method.
[0160] [Table 3]
[0161]
[0162] <Calculation of solubilization rate>
[0163] Using the above results, the solubilization rate of the added ellagic acid in Examples A1 to A4 and Comparative Example A1 was calculated. The solubilization rate was calculated based on the solubilization rate when DMSO was used as a solvent. The solubilization rate when DMSO was used as a solvent is the value (80.3 μg / mL) obtained by subtracting the ellagic acid concentration (101.5 μg / mL) of the liquid composition C-D1 of Comparative Example D1 from the liquid composition C-B2 (21.2 μg / mL) of Comparative Example B2. Specifically, the solubilization rate of the dissolved portion of the added ellagic acid was calculated by subtracting the ellagic acid concentration obtained in the corresponding example from the ellagic acid concentration obtained in the example or the comparative example, and the solubilization rate (%) was calculated by dividing the solubilization rate by the above 80.3 μg / mL and multiplying by 100. It should be noted that Example A1 corresponds to Example B1, Example A2 corresponds to Example B2, Example A3 corresponds to Example B3, Example A4 corresponds to Example B4, and Comparative Example A1 corresponds to Comparative Example B1. Table 4 shows the calculated solubilization ratios.
[0164] [Table 4]
[0165] Solubilization rate % Example A1 101.8 Example A2 60.1 Example A3 108.1 Example A4 14.1 Comparative Example A1 8.0
[0166] (Inspection)
[0167] As shown in Examples A1 to A4, it was confirmed that by adding ellagic acid to the extract from the genus Terminalia and heating it, the added ellagic acid can be dissolved at a high concentration. This is presumably because the extract from the genus Terminalia contains a component that solubilizes ellagic acid, and heating in the presence of this component can solubilize ellagic acid.
[0168] [Study on improving the solubility of ellagic acid 2]
[0169] (Example A5)
[0170] Liquid composition E-A5 was obtained in the same manner as in Example A1 except that the extract-containing solution (10 mg / mL, containing an aqueous extract) prepared in Preparation Example 2 was used.
[0171] (Example A6)
[0172] Liquid composition E-A6 was obtained in the same manner as in Example A5, except that heating at 121° C. was performed using an autoclave instead of heating with a dry bath.
[0173] (Example A7)
[0174] Liquid composition E-A7 was obtained in the same manner as in Example A1 except that the extract-containing solution prepared in Preparation Example 3 (10 mg / mL, containing 100% ethanol extract) was used.
[0175] (Example A8)
[0176] Liquid composition E-A8 was obtained in the same manner as in Example A7, except that heating at 121° C. was performed using an autoclave instead of heating with a dry bath.
[0177] (Example B5)
[0178] Liquid composition E-B5 was obtained in the same manner as in Example B1 except that the extract-containing solution (10 mg / mL, containing an aqueous extract) prepared in Preparation Example 2 was used.
[0179] (Example B6)
[0180] Liquid composition E-B6 was obtained in the same manner as in Example B5, except that heating at 121° C. was performed using an autoclave instead of heating with a dry bath.
[0181] (Example B7)
[0182] Liquid composition E-B7 was obtained in the same manner as in Example B1 except that the extract-containing solution prepared in Preparation Example 3 (10 mg / mL, containing 100% ethanol extract) was used.
[0183] (Example B8)
[0184] Liquid composition E-B8 was obtained in the same manner as in Example B7, except that heating at 121° C. was performed using an autoclave instead of heating with a dry bath.
[0185] (Comparative Example E1)
[0186] A liquid composition C-E1 was obtained in the same manner as in Example A5, except that the mixture was left at room temperature (23° C.) for 20 minutes without heating with a dry bath.
[0187] (Comparative Example E2)
[0188] Liquid composition C-E2 was obtained in the same manner as in Example A7 except that the mixture was left at room temperature (23° C.) for 20 minutes without heating with a dry bath.
[0189] (Comparative Example E3)
[0190] Liquid composition C-E3 was obtained in the same manner as in Example B5 except that the mixture was left at room temperature (23° C.) for 20 minutes without heating with a dry bath.
[0191] (Comparative Example E4)
[0192] Liquid composition C-E4 was obtained in the same manner as in Example B7 except that the mixture was left at room temperature (23° C.) for 20 minutes without heating with a dry bath.
[0193] (Comparative Example F1)
[0194] A liquid composition C-F1 was obtained in the same manner as in Comparative Example D1 except that the extract-containing solution (10 mg / mL, containing an aqueous extract) prepared in Preparation Example 2 was used.
[0195] (Comparative Example F2)
[0196] A liquid composition C-F2 was obtained in the same manner as in Comparative Example D1 except that the extract-containing solution prepared in Preparation Example 3 (10 mg / mL, containing 100% ethanol extract) was used.
[0197] (Comparative Example F3)
[0198] A liquid composition C-F3 was obtained in the same manner as in Comparative Example B2 except that the extract-containing solution (10 mg / mL, containing an aqueous extract) prepared in Preparation Example 2 was used.
[0199] (Comparative Example F4)
[0200] A liquid composition C-F4 was obtained in the same manner as in Comparative Example B2 except that the extract-containing solution prepared in Preparation Example 3 (10 mg / mL, containing 100% ethanol extract) was used.
[0201] (evaluate)
[0202] <Determination of ellagic acid concentration>
[0203] The ellagic acid concentration of the obtained liquid composition was measured according to the above-mentioned measurement method.
[0204] [Table 5]
[0205]
[0206]
[0207] <Calculation of solubilization rate>
[0208] Using the above results, the solubilization rates of the added ellagic acid parts in Examples A5 to A8 and Comparative Examples E1 to E2 were calculated in the same manner as above. It should be noted that Example A5 corresponds to Example B5, Example A6 corresponds to Example B6, Example A7 corresponds to Example B7, Example A8 corresponds to Example B8, Comparative Example E1 corresponds to Comparative Example E3, and Comparative Example E2 corresponds to Comparative Example E4. In the calculation of the solubilization rate of Example A5, Example A6, and Comparative Example E1, the solubilization rate when DMSO was used as the solvent was the value (87.3 μg / mL) obtained by subtracting the ellagic acid concentration (18.4 μg / mL) of Comparative Example F3 from the ellagic acid concentration (105.7 μg / mL) of Comparative Example F1, and in the calculation of the solubilization rate of Example A7, Example A8, and Comparative Example E2, the solubilization rate when DMSO was used as the solvent was the value (101.5 μg / mL) obtained by subtracting the ellagic acid concentration (22.0 μg / mL) of Comparative Example F4 from the ellagic acid concentration (123.5 μg / mL) of Comparative Example F2. The calculated solubilization rates are shown in Table 6.
[0209] [Table 6]
[0210]
[0211] (Inspection)
[0212] As shown in Examples A5 to A8, the solubilization rate of ellagic acid was improved even when extracts obtained with water and 100% ethanol were used. As a result, the solubilization rate of ellagic acid was higher in the case of the extract using water than in the case of the extract using 100% ethanol.
[0213] [Study on improving the solubility of ellagic acid 3]
[0214] (Example A9)
[0215] In a 1.5 mL tube, a solution is prepared by mixing 50 μL of the solution containing ellagic acid (1 mg / mL) prepared in the above-mentioned Preparation Example 4 (equivalent to 50 μg of ellagic acid) and 50 μL of the solution containing the extract (10 mg / mL, containing 50% ethanol extract) prepared in the above-mentioned Preparation Example 1 (equivalent to 500 μg of extract). The solution in the tube is subjected to reduced pressure centrifugation to remove the solvent, and a powder containing the extract is prepared. Then, 500 μL of pure water is added to the tube and mixed with the extract-containing powder to prepare a mixed solution. Then, the tube containing the mixed solution is placed in a dry bath and incubated at 95°C for 20 minutes. Then, the incubated mixed solution is placed in the surrounding environment and returned to room temperature (23°C). Then, the mixed solution in the tube is concentrated by reduced pressure centrifugation to a volume of about 1 / 10. Thereafter, the mixed solution is filtered with a 0.45 um filter to remove solids to obtain a liquid composition E-A9.
[0216] (Example A10)
[0217] Liquid composition E-A10 was obtained in the same manner as in Example A9, except that the extract-containing solution (10 mg / mL, containing 50% ethanol extract) prepared in Preparation Example 2 was used instead of the extract-containing solution (10 mg / mL, containing water extract) prepared in Preparation Example 1.
[0218] (evaluate)
[0219] <Determination of ellagic acid concentration>
[0220] The ellagic acid concentration of the obtained liquid composition was measured according to the above-mentioned measurement method. The results are shown in Table 7.
[0221] [Table 7]
[0222]
[0223] (Inspection)
[0224] As shown in Examples A9 to A10, it was confirmed that a composition containing an extract from a plant of the genus Terminalia that had been subjected to a heat treatment could be further concentrated to obtain a composition containing ellagic acid at a higher concentration. Considering that the solubility of ellagic acid in water is about 20 μg / mL, it can be understood that the solubilization effect of ellagic acid obtained by heating the extract from the genus Terminalia is extremely significant.
[0225] The upper limit and / or lower limit of the numerical range recorded in this specification can be arbitrarily combined to define a preferred range. For example, the upper limit and lower limit of the numerical range can be arbitrarily combined to define a preferred range, the upper limits of the numerical range can be arbitrarily combined with each other to define a preferred range, and the lower limits of the numerical range can be arbitrarily combined with each other to define a preferred range.
[0226] The claims attached to the disclosure recorded in this article are expressly incorporated into the disclosure recorded in this specification, and each claim is independent as a separate embodiment. The present disclosure includes all the contents after the independent claim is replaced by its dependent claims. Further, additional embodiments derived from the independent claim and its subsequent dependent claims are also expressly incorporated into the specification recorded in this article.
[0227] Those skilled in the art may use the above description in order to make the most of the present disclosure. The scope of the claims and the embodiments disclosed in this specification are illustrative and exemplary only and should be interpreted as not limiting the scope of the present disclosure in any sense. With the help of this disclosure, changes can be added to the details of the above embodiments without departing from the basic principles of the present disclosure. In other words, various changes and improvements to the embodiments specifically disclosed in the above description are within the scope of the present disclosure.
[0228] Although the present embodiment has been described in detail above, the specific configuration is not limited to the embodiment, and even if there are design changes within the scope that does not depart from the gist of the present disclosure, they are included in the present disclosure.
Claims
1. A method for producing a composition containing ellagic acid, comprising: A step of preparing a solution containing a raw material derived from a plant of the genus Terminalia containing at least ellagic acid and an aqueous medium; as well as A step of subjecting the solution to a heat treatment.
2. The manufacturing method according to claim 1, further comprising: A step of performing a hydrolysis treatment to hydrolyze ellagitannins contained in the raw material to generate more ellagic acid, The solution subjected to the hydrolysis treatment is subjected to a heating treatment.
3. The manufacturing method according to claim 2, wherein: The hydrolysis treatment is an acid-based hydrolysis.
4. The production method according to any one of claims 1 to 3, wherein The solution further contains ellagic acid added separately from the ellagic acid contained in the raw material derived from the plant of the genus Terminalia.
5. The production method according to any one of claims 1 to 4, wherein The plant of the genus Terminalia is Terminalia catappa.
6. The production method according to any one of claims 1 to 5, wherein The raw material derived from the Terminalia genus plant is at least one material selected from the leaves, fruits, trunks and branches of the Terminalia genus plant, or an extract extracted from at least one material selected from the leaves, fruits, trunks and branches of the Terminalia genus plant using an extraction medium.
7. The production method according to any one of claims 1 to 6, wherein The raw material derived from the Terminalia genus plant is an extract extracted from at least one material selected from the group consisting of leaves, fruits, trunks and branches of the Terminalia genus plant using an extraction medium.
8. The manufacturing method according to claim 6 or 7, wherein: The extraction medium is water, an aqueous medium or a mixed solvent thereof.
9. The production method according to any one of claims 6 to 8, wherein The extraction medium is water, alcohol or a mixed solvent of water and alcohol.
10. The production method according to any one of claims 1 to 9, wherein: The temperature of the heat treatment is 60° C. or higher.
11. The production method according to any one of claims 1 to 10, wherein The temperature of the heat treatment is lower than 100°C.
12. The production method according to any one of claims 1 to 11, wherein The aqueous medium in the solution is water, alcohol or a mixed solvent of water and alcohol.
13. The production method according to any one of claims 1 to 12, wherein: After the step of performing the heating treatment, the method further includes the step of performing a concentration treatment on the solution.
14. The production method according to any one of claims 1 to 13, wherein The concentration of ellagic acid dissolved in the solution obtained by the step of performing the heating treatment or, in the case of performing the concentration treatment, the step of performing the concentration treatment is 50 μg / mL or more.
15. The production method according to any one of claims 1 to 14, wherein After the step of performing the heating treatment or, in the case of performing the concentration treatment, after the step of performing the concentration treatment, the method further includes the step of drying the solution to obtain an ellagic acid-containing solid. 16 . An ellagic acid-containing composition obtained by the production method according to claim 1 .
17. A medicine, cosmetic, quasi-drug, or food or beverage comprising the ellagic acid-containing composition according to claim 16.
18. Use of a raw material from Terminalia genus for solubilizing ellagic acid, wherein: A solution containing a raw material derived from a plant of the genus Terminalia and an aqueous medium is subjected to a heat treatment in the presence of ellagic acid.
Citation Information
Patent Citations
Method for producing ellagic acid composition
CN105357983A
Method for preparing ellagic acid by pomegranate rind
CN1803801A
Method for producing ellagic acid
JP2002205993A
